Bone Metastasis in Solid Tumor Market Size (7MM) was USD 1700 Million in 2023 and It is projected to grow at a significant CAGR by 2034, estimates DelveInsight

The Bone Metastasis in Solid Tumor Market Size in the 7MM was ~USD 1700 Million in 2023 and is projected to increase during the study period (2020–2034), with a significant CAGR. DelveInsight’s Comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Bone Metastasis in Solid Tumor Market Landscape. By analyzing historical data, current Bone Metastasis in Solid Tumor Market Dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

DelveInsight’s “Bone Metastasis in Solid Tumor Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of Bone Metastasis in Solid Tumor, historical and forecasted epidemiology, as well as the Bone Metastasis in Solid Tumor Market Trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover more about the epilepsy market in detail @ Bone Metastasis in Solid Tumor Market Report

Key Takeaways from the Bone Metastasis in Solid Tumor Market Report

• In April 2026- Actuate Therapeutics Inc. initiated a Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.
• Among the 7MM, the United States accounted for the highest Bone Metastasis in Solid Tumors market size in 2023, followed by Japan for bone metastasis in solid tumors.
• During the forecast period (2024–2034), approval of Bone Metastasis in Solid Tumors pipeline candidates such as Cabozantinib is expected to drive the rise in bone metastasis in the solid tumor market size.
• In 7MM, the United States accounted for the highest number of total incident cases of Bone metastasis in Solid Tumors in 2023.
• The United States accounted for more cases of bone metastasis in solid tumors in females than in males in 2023.
• Among the EU4 and the UK, Germany accounted for the highest number of cases of bone metastasis in solid tumors, followed by France. In contrast, Spain accounted for the lowest number of cases in 2023.
• In Japan, lung cancer accounted for the highest number of cases of bone metastasis, followed by Breast cancer and Prostate cancer in 2023.
• The leading Bone Metastasis in Solid Tumor Companies such as Mabwell (Shanghai) Bioscience Co., Ltd., Novartis, Institut Bergonié, Pfizer, GlaxoSmithKline, Amgen, QSAM Therapeutics Inc., Actuate Therapeutics Inc., Hoffmann-La Roche, and others.
• Promising Bone Metastasis in Solid Tumor Therapies such as MW032, Xgeva, Ibandronate, Zoledronic acid, Entrectinib, AMG 479, and others.

Get a Free sample for the Bone Metastasis in Solid Tumor Market Report @ Bone Metastasis in Solid Tumor Therapeutics Market

Bone Metastasis in Solid Tumor Overview

Bone metastasis in solid tumors refers to the spread of cancer cells from a primary solid tumor (such as breast, prostate, or lung cancer) to the bones. It is not a new type of cancer, but rather an advanced stage of the original cancer where malignant cells migrate through the bloodstream or lymphatic system and establish secondary tumors in bone tissue. Cancer cells break away from the primary tumor, travel through circulation, and settle in bones—commonly the spine, pelvis, ribs, or long bones. Once there, they disrupt the normal balance between bone formation and breakdown.

Bone Metastasis in Solid Tumor Epidemiology Segmentation in the 7MM

• Total Bone Metastasis in Solid Tumors incident cases
• Bone Metastasis in Solid Tumors Region-specific cases
• Bone Metastasis in Solid Tumors Solid tumor type-specific cases
• Bone Metastasis in Solid Tumors Gender-specific cases

Download the report to understand which factors are driving Bone Metastasis in Solid Tumor Epidemiology trends @ Bone Metastasis in Solid Tumor Prevalence

Bone Metastasis in Solid Tumors Marketed Therapies

• XOFIGO (Radium-223 dichloride): Bayer HealthCare Pharmaceuticals

XOFIGO, formerly Alpharadin, represents an alpha particle-emitting radioactive therapeutic agent. It is the first FDA-approved α-particle emitter therapeutic agent. XOFIGO has demonstrated significant advantages, including improvements in overall survival and a delay in symptomatic skeletal events for individuals with metastatic castrate-resistant prostate cancer (CRPC). The active moiety of XOFIGO is the alpha particle-emitting isotope radium-223 (as radium Ra 223 dichloride), which mimics calcium and forms complexes with the bone mineral hydroxyapatite at areas of increased bone turnover, such as bone metastases. The high linear energy transfer of alpha particles (80 keV/micrometer) leads to a high frequency of double-strand DNA breaks in adjacent cells, including tumor cells, osteoblasts, and osteoclasts, resulting in an antitumor effect on bone metastases. The alpha particle range from radium-223 dichloride is less than 100 µm (less than 10 cell diameters), limiting damage to the surrounding normal tissue.

• XGEVA/RANMARK (denosumab): Amgen

XGEVA is a RANK ligand (RANKL) inhibitor indicated for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors. It is a fully human monoclonal antibody that binds to RANK Ligand, a protein essential for the formation, function, and survival of osteoclasts (the cells that break down bone). XGEVA prevents RANK Ligand from activating its receptor, RANK, on the surface of osteoclasts, thereby decreasing bone destruction. XGEVA binds to RANKL, a transmembrane or soluble protein essential for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption, thereby modulating calcium release from bone.

Bone Metastasis in Solid Tumors Emerging Therapies

• Cabozantinib: Exelixis

Cabozantinib inhibits MET, VEGFR2, and RET, proteins that are key drivers of tumor growth, vascularization and/or metastasis. Cabozantinib has shown novel and differentiated activity in multiple cancer indications. The current clinical program for cabozantinib is focused on the treatment of metastatic castration-resistant prostate cancer, or CRPC, and medullary thyroid cancer but also includes the evaluation of other tumor types. Exelixis has implemented a strategy to investigate cabozantinib in a comprehensive development program for CRPC to potentially generate a product that could effectively compete in the CRPC marketplace.

Discover more about therapies set to grab major Bone Metastasis in Solid Tumor Market Share @ Bone Metastasis in Solid Tumor Market Drivers and Barriers

Bone Metastasis in Solid Tumors Market Outlook

Bone is a recurrent site of metastatic disease in advanced cancer patients. Although bone metastases could occur in conjunction with any solid tumor, they are most commonly observed in breast, prostate, lung cancer, and renal cell carcinoma patients. Clinical management of patients with bone metastases focuses primarily on palliating pain, preventing bone complications, and maintaining the quality of life. Bone-targeting agents (BTA) are one of the most frequently used forms of treatment for bone metastasis of solid tumors, where they provide prevention of SREs in patients with bone metastasis. BTA’s include XGEVA (denosumab) and bisphosphonates, like zoledronic acid, pamidronate, ibandronate, clodronate, and alendronate

Bone Metastasis in Solid Tumors Disease Therapeutics Market

The ability of cancer cells to leave a primary tumor, disseminate through the body, and seed new secondary tumors is universally recognized as the basis for metastasis formation. Bone metastasis is a secondary cancer in the bone that commonly occurs in conjunction with solid tumors and is associated with serious bone complications. Bone metastasis typically occurs in breast, lung, prostate, thyroid, and renal carcinoma, and the bone is the third most prevalent site of metastasis after the liver and lung. Bone metastasis may cause complications such as pain, nerve root or spine cord compression, vertebral or peripheral fractures, hypercalcemia, and bone marrow infiltration that leads to cytopenia.

Get exclusive access to detailed forecasts, Bone Metastasis in Solid Tumor Market Dynamics, and competitive intelligence by requesting the full report @ Bone Metastasis in Solid Tumor Market Access and Reimbursement

Scope of the Bone Metastasis in Solid Tumor Market Report

• Coverage- 7MM
• Study Period- 2020-2034
• Bone Metastasis in Solid Tumor Companies- Mabwell (Shanghai) Bioscience Co., Ltd., Novartis, Institut Bergonié, Pfizer, GlaxoSmithKline, Amgen, QSAM Therapeutics Inc., Actuate Therapeutics Inc., Hoffmann-La Roche, and others.
• Bone Metastasis in Solid Tumor Therapies- MW032, Xgeva, Ibandronate, Zoledronic acid, Entrectinib, AMG 479 and others.
• Bone Metastasis in Solid Tumor Therapeutic Assessment: Bone Metastasis in Solid Tumor current marketed and Bone Metastasis in Solid Tumor Emerging Therapies
• Bone Metastasis in Solid Tumor Market Dynamics: Bone Metastasis in Solid Tumor Market Drivers and Bone Metastasis in Solid Tumor Market Barriers
• Bone Metastasis in Solid Tumor Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Bone Metastasis in Solid Tumor Unmet Needs, KOL's views, Analyst's views, Bone Metastasis in Solid Tumor Market Access and Reimbursement

To know more about Bone Metastasis in Solid Tumor Companies working in the treatment market, visit @ Bone Metastasis in Solid Tumor Market Access and Reimbursement

Table of Contents

1. Key Insights
2. Report Introduction
3. Bone Metastasis in Solid Tumor Market Overview at a Glance
4. Methodology of Bone Metastasis in Solid Tumor Epidemiology and Market
5. Executive Summary
6. Key Events
7. Disease Background and Overview
8. Bone Metastasis in Solid Tumor Patient Journey
9. Bone Metastasis in Solid Tumor Epidemiology and Patient Population
10. Bone Metastasis in Solid Tumor Marketed Drugs
11. Bone Metastasis in Solid Tumor Emerging Drugs
12. Bone Metastasis in Solid Tumor Market Analysis
13. Key Opinion Leaders’ Views
14. SWOT Analysis
15. Bone Metastasis in Solid Tumor Unmet Needs
16. Bone Metastasis in Solid Tumor Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.5